Claim 70% Off TipRanks This Holiday Season
- Unlock hedge fund-level data and powerful investing tools for smarter, sharper decisions
- Stay ahead of the market with the latest news and analysis and maximize your portfolio's potential
Santen Pharmaceutical Co ( (JP:4536) ) has shared an update.
Santen Pharmaceutical Co., Ltd. announced the cancellation of 19.8 million treasury shares, representing 5.8% of its outstanding shares, effective November 28, 2025. This strategic move is expected to impact the company’s share structure, reducing the total number of outstanding shares to approximately 322.3 million, which could potentially influence shareholder value and market perception.
The most recent analyst rating on (JP:4536) stock is a Hold with a Yen1688.00 price target. To see the full list of analyst forecasts on Santen Pharmaceutical Co stock, see the JP:4536 Stock Forecast page.
More about Santen Pharmaceutical Co
Santen Pharmaceutical Co., Ltd. is a specialized company dedicated to eye health, providing products and services to patients, consumers, and medical professionals globally. With over 130 years of experience, Santen is involved in the research, development, manufacturing, and marketing of pharmaceutical products in the field of eye care, supporting the eye health of approximately 50 million people in more than 60 countries. The company is committed to enhancing the prevention, diagnosis, and treatment of eye diseases, aiming to create a future where people can experience ‘Happiness with Vision.’
Average Trading Volume: 1,518,848
Technical Sentiment Signal: Buy
Current Market Cap: Yen520.3B
For detailed information about 4536 stock, go to TipRanks’ Stock Analysis page.